Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase

Journal of Biomolecular Screening

Volumn 21, Issue 7, 2016, Pages 689-694

  Klingler, Franca Maria ^a   Wolf, Markus ^b   Wittmann, Sandra ^a   Gribbon, Philip ^b   Proschak, Ewgenij ^a  

^a GOETHE UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

enzyme assay; high throughput screening; phosphatase; soluble epoxide hydrolase

Indexed keywords

EPOXIDE HYDROLASE; EPOXIDE HYDROLASE PHOSPHATASE; PHOSPHATASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EPHX2 PROTEIN, HUMAN;

ALKALINITY; AMINO TERMINAL SEQUENCE; ARTICLE; DOSE RESPONSE; ENZYME ASSAY; ENZYME KINETICS; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; IC50; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; TURNOVER TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MOUSE; PROCEDURES; SOLUBILITY;

ANIMALS; CATALYTIC DOMAIN; ENZYME INHIBITORS; EPOXIDE HYDROLASES; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; PHOSPHORIC MONOESTER HYDROLASES; SOLUBILITY;

EID: 84979300146     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116637609     Document Type: Article

References (30)

1. Fleming I., The Pharmacology of the Cytochrome P450 Epoxygenase/Soluble Epoxide Hydrolase Axis in the Vasculature and Cardiovascular Disease. Pharmacol. Rev. 2014, 66, 1106-1140.
2. Shen H. C., Hammock B. D., Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications. J. Med. Chem. 2012, 55, 1789-1808.
3. Cronin A., Mowbray S., Dürk H., et al. The N-Terminal Domain of Mammalian Soluble Epoxide Hydrolase Is a Phosphatase. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1552-1557.
4. Newman J. W., Morisseau C., Harris T. R., et al. The Soluble Epoxide Hydrolase Encoded by EPXH2 Is a Bifunctional Enzyme with Novel Lipid Phosphate Phosphatase Activity. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 1558-1563.
5. Cronin A., Homburg S., Dürk H., et al. Insights into the Catalytic Mechanism of Human sEH Phosphatase by Site-Directed Mutagenesis and LC-MS/MS Analysis. J. Mol. Biol. 2008, 383, 627-640.
6. Enayetallah A. E., Grant D. F., Effects of Human Soluble Epoxide Hydrolase Polymorphisms on Isoprenoid Phosphate Hydrolysis. Biochem. Biophys. Res. Commun. 2006, 341, 254-260.
7. Oguro A., Imaoka S., Lysophosphatidic Acids Are New Substrates for the Phosphatase Domain of Soluble Epoxide Hydrolase. J. Lipid Res. 2012, 53, 505-512.
8. Morisseau C., Schebb N. H., Dong H., et al. Role of Soluble Epoxide Hydrolase Phosphatase Activity in the Metabolism of Lysophosphatidic Acids. Biochem. Biophys. Res. Commun. 2012, 419, 796-800.
9. Luria A., Morisseau C., Tsai H.-J., et al. Alteration in Plasma Testosterone Levels in Male Mice Lacking Soluble Epoxide Hydrolase. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E375-E383.
10. Keserü B., Barbosa-Sicard E., Schermuly R. T., et al. Hypoxia-Induced Pulmonary Hypertension: Comparison of Soluble Epoxide Hydrolase Deletion vs. Inhibition. Cardiovasc. Res. 2010, 85, 232-240.
11. Oguro A., Sakamoto K., Suzuki S., et al. Contribution of Hydrolase and Phosphatase Domains in Soluble Epoxide Hydrolase to Vascular Endothelial Growth Factor Expression and Cell Growth. Biol. Pharm. Bull. 2009, 32, 1962-1967.
12. Hou H.-H., Hammock B. D., Su K.-H., et al. N-Terminal Domain of Soluble Epoxide Hydrolase Negatively Regulates the VEGF-Mediated Activation of Endothelial Nitric Oxide Synthase. Cardiovasc. Res. 2011, 93, 120-129.
13. Hou H.-H., Liao Y.-J., Hsiao S.-H., et al. Role of Phosphatase Activity of Soluble Epoxide Hydrolase in Regulating Simvastatin-Activated Endothelial Nitric Oxide Synthase. Sci. Rep. 2015, 5, 13524.
14. Srivastava P. K., Sharma V. K., Kalonia D. S., et al. Polymorphisms in Human Soluble Epoxide Hydrolase: Effects on Enzyme Activity, Enzyme Stability, and Quaternary Structure. Arch. Biochem. Biophys. 2004, 427, 164-169.
15. Purba E. R., Leuhery E. A., Oguro A., et al. The Metabolism of Lysophosphatidic Acids by Allelic Variants of Human Soluble Epoxide Hydrolase. Drug Metab. Pharmacokinet. 2015, 30, 75-81.
16. Arrowsmith C. H., Audia J. E., Austin C., et al. The Promise and Peril of Chemical Probes. Nat. Chem. Biol. 2015, 11, 536-541.
17. Newman J. W., Morisseau C., Harris T. R., et al. The Soluble Epoxide Hydrolase Encoded by EPXH2 Is a Bifunctional Enzyme with Novel Lipid Phosphate Phosphatase Activity. Proc. Natl. Acad. Sci. 2003, 100, 1558-1563.
18. Tran K. L., Aronov P. A., Tanaka H., et al. Lipid Sulfates and Sulfonates Are Allosteric Competitive Inhibitors of the N-Terminal Phosphatase Activity of the Mammalian Soluble Epoxide Hydrolase. Biochemistry (Mosc.) 2005, 44, 12179-12187.
19. Morisseau C., Sahdeo S., Cortopassi G., et al. Development of an HTS Assay for EPHX2 Phosphatase Activity and Screening of Nontargeted Libraries. Anal. Biochem. 2013, 434, 105-111.
20. Azad G. K., Tomar R. S., Ebselen, a Promising Antioxidant Drug: Mechanisms of Action and Targets of Biological Pathways. Mol. Biol. Rep. 2014, 41, 4865-4879.
21. Matsumoto N., Suzuki E., Ishikawa M., et al. Soluble Epoxide Hydrolase as an Anti-Inflammatory Target of the Thrombolytic Stroke Drug SMTP-7. J. Biol. Chem. 2014, 289, 35826-35838.
22. Matsumoto N., Suzuki E., Tsujihara K., et al. Structure-Activity Relationships of the Plasminogen Modulator SMTP with Respect to the Inhibition of Soluble Epoxide Hydrolase. J. Antibiot. (Tokyo) 2015, 68, 685-690.
23. Lisurek M., Rupp B., Wichard J., et al. Design of Chemical Libraries with Potentially Bioactive Molecules Applying a Maximum Common Substructure Concept. Mol. Divers. 2010, 14, 401-408.
24. Hahn S., Achenbach J., Buscató E. l., et al. Complementary Screening Techniques Yielded Fragments That Inhibit the Phosphatase Activity of Soluble Epoxide Hydrolase. ChemMedChem 2011, 6, 2146-2149.
25. Huang Z., 3,6-Fluorescein Diphosphate: A Sensitive Fluorogenic and Chromogenic Substrate for Protein Tyrosine Phosphatases. J. Biomol. Screen. 1999, 4, 327-334.
26. Iversen P. W., Eastwood B. J., Sittampalam G. S., et al. A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z′ Factor, and Assay Variability Ratio. J. Biomol. Screen. 2006, 11, 247-252.
27. Jadhav A., Ferreira R. S., Klumpp C., et al. Quantitative Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen for Inhibitors of a Thiol Protease. J. Med. Chem. 2010, 53, 37-51.
28. Feng B. Y., Shoichet B. K., A Detergent-Based Assay for the Detection of Promiscuous Inhibitors. Nat. Protoc. 2006, 1, 550-553.
29. Baell J., Walters M. A., Chemical Con Artists Foil Drug Discovery. Nature 2014, 513, 481-483.
30. Cronin A., Homburg S., Dürk H., et al. Insights into the Catalytic Mechanism of Human sEH Phosphatase by Site-Directed Mutagenesis and LC-MS/MS Analysis. J. Mol. Biol. 2008, 383, 627-640.